Navigate Up

UPMC/University of Pittsburgh Schools of the Health Sciences
Manager
Telephone: 412-623-4701 or 412-586-9773

Patients and medical professionals may call 1-800-533-UPMC (8762) for more information.

Cyberknife Radiosurgery Is A Safe And Effective Treatment For Benign Tumors, According To University Of Pittsburgh Study​

ATLANTA, October 5, 2004 Treating benign tumors outside the brain with CyberKnife Frameless Radiosurgery resulted in significant improvement in symptoms and minimal toxicity, according to a study by University of Pittsburgh School of Medicine researchers presented today at the 46th Annual Meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO) in Atlanta.

While stereotactic radiosurgery for the treatment of benign brain tumors has become widely accepted, our knowledge about the use of this technology for benign tumors outside the brain has been limited, said Steve Burton, M.D., study co-author and assistant professor, department of radiation oncology, University of Pittsburgh School of Medicine. The results of our study indicate that treating these tumors with CyberKnife is safe and effective and can successfully control their growth and progression.

The study, whose purpose was to evaluate the feasibility, toxicity and local control of patients with symptomatic benign tumors treated with CyberKnife, evaluated 50 benign tumors in 35 patients who underwent radiosurgery between 2001 and 2004 at the University of Pittsburgh Medical Center. The tumors were located in the spine (36), neck (6), skull (3), eye (3) and brainstem (2). Seventy-eight percent of patients treated with CyberKnife experienced an improvement in their pre-treatment symptoms, which included pain and weakness. The local control rate the rate at which the tumors growth was controlled locally was 96 percent for the 26 patients who underwent follow-up imaging from one to 25 months after the treatment was administered.

Our findings demonstrate that CyberKnife may offer a promising treatment option for patients with benign tumors who are not candidates for surgery or whose tumors are not amenable to surgery, said Dr. Burton. The potential benefits are significant and include short-term treatment time in an outpatient setting with rapid recovery and symptomatic response.

Dr. Burton added that follow-up studies will seek to assess the long-term tumor control rates as well as any future effects.

This study represents the largest to date on the use of frameless radiosurgery to treat benign extra-cranial lesions, and the results thus far are very encouraging. Of noteworthy interest, CyberKnife was able to control aggressive benign tumors that had progressed despite surgery and/or conventional radiation, said Ajay Bhatnagar, M.D., resident, department of radiation oncology, University of Pittsburgh School of Medicine.

CyberKnife is a non-invasive robotic radiosurgical device that can remove tumors and other lesions without open surgery, using a robotic arm, controlled by a computer, that sends multiple beams of high-dose radiation directly to the tumor site.

Also involved in the study from the University of Pittsburgh were Peter Gerszten, M.D, department of neurological surgery; Anurag Agarwal, M.D., department of radiation oncology; C.W. Ozhasoglu, M.D., department of radiation oncology; William Vogel, R.T.T., department of radiation oncology; W.C. Welch, M.D., department of neurological surgery; and Shalom Kalnicki, M.D., now of the department of radiation oncology, Montefiore Medical Center, New York.

©  UPMC | Affiliated with the University of Pittsburgh Schools of the Health Sciences
Supplemental content provided by A.D.A.M. Health Solutions. All rights reserved.

For help in finding a doctor or health service that suits your needs, call the UPMC Referral Service at 412-647-UPMC (8762) or 1-800-533-UPMC (8762). Select option 1.

UPMC is an equal opportunity employer. UPMC policy prohibits discrimination or harassment on the basis of race, color, religion, ancestry, national origin, age, sex, genetics, sexual orientation, marital status, familial status, disability, veteran status, or any other legally protected group status. Further, UPMC will continue to support and promote equal employment opportunity, human dignity, and racial, ethnic, and cultural diversity. This policy applies to admissions, employment, and access to and treatment in UPMC programs and activities. This commitment is made by UPMC in accordance with federal, state, and/or local laws and regulations.

Medical information made available on UPMC.com is not intended to be used as a substitute for professional medical advice, diagnosis, or treatment. You should not rely entirely on this information for your health care needs. Ask your own doctor or health care provider any specific medical questions that you have. Further, UPMC.com is not a tool to be used in the case of an emergency. If an emergency arises, you should seek appropriate emergency medical services.

For UPMC Mercy Patients: As a Catholic hospital, UPMC Mercy abides by the Ethical and Religious Directives for Catholic Health Care Services, as determined by the United States Conference of Catholic Bishops. As such, UPMC Mercy neither endorses nor provides medical practices and/or procedures that contradict the moral teachings of the Roman Catholic Church.

© UPMC
Pittsburgh, PA, USA UPMC.com